Entecavir as a first-line treatment for hepatitis B virus reactivation following polychemotherapy for chronic lymphocytic leukemia and invasive ductal carcinoma: A report of two cases and review of the literature

European Journal of Gastroenterology and Hepatology

Volumn 27, Issue 1, 2015, Pages 39-45

  Türker, Kamuran ^a   Albayrak, Murat ^b   Öksüzoʇlu, Berna ^c   Balci, Elc¸in ^d   Oʇan, Mustafa C ^c   Iskender, Gülşen ^c   Altuntaş, Fevzi ^c  

^a Department of Infectious Diseases Istanbul Ba cilar Training and Research Hospital   (Turkey)

^b DISKAPI YILDIRIM BEYAZIT TRAINING AND RESEARCH HOSPITAL   (Turkey)

^c ANKARA ONCOLOGY HOSPITAL   (Turkey)

^d ERCIYES UNIVERSITY MEDICAL FACULTY   (Turkey)

Author keywords

Antiviral treatment; Breast cancer; Hepatitis B infection; Immunosuppression; Leukemia; Lymphoma

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; ENTECAVIR; FLUDARABINE; FLUOROURACIL; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; GUANINE; HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIGEN;

ADULT; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ARTICLE; BREAST CARCINOMA; CASE REPORT; CHRONIC LYMPHATIC LEUKEMIA; COMBINATION CHEMOTHERAPY; DISEASE CONTROL; FEMALE; HEPATITIS B; HUMAN; LONG TERM CARE; LYMPHADENOPATHY; MALE; MULTIPLE CYCLE TREATMENT; PROTHROMBIN TIME; SEROCONVERSION; VIRUS LOAD; VIRUS REACTIVATION; ANALOGS AND DERIVATIVES; BLOOD; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; COMPLICATION; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; IMMUNOLOGY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MIDDLE AGED; PHYSIOLOGY; RECURRENT DISEASE; VIRUS ACTIVATION;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIVIRAL AGENTS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; GUANINE; HEPATITIS B ANTIBODIES; HEPATITIS B CORE ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; RECURRENCE; VIRUS ACTIVATION;

EID: 84916612992     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0000000000000115     Document Type: Article

References (36)

1. Lai CL, Ratzui V, Yuen MF, Poynard T. Viral hepatitis B. Lancet 2003; 362:2089-2094.
2. World Health Organization. Hepatitis B. Geneva: World Health Organization 2000; Factsheet no. 204.
3. Lalazar G, Rund D, Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 2007; 136:699-712.
4. Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F, Csako G. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008; 148:519-528.
5. Shibolet O, Ilan Y, Gillis S, Hubert A, Shouval D, Safadi R. Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood 2002; 100:391-396.
6. Ozaslan M, Ozaslan E, Barsgan A, Koruk M. Mutations in the S gene region of hepatitis B virus genotype D in Turkish patients. J Genet 2007; 86:195-201.
7. Watanabe M, Shibuya A, Takada J, Tanaka Y, Okuwaki Y, Minamino T, et al. Entecavir is an optional agent to prevent hepatitis B virus (HBV) reactivation: a review of 16 patients. Eur J Intern Med 2010; 21:333-337.
8. Montineri A, Nigro L, La Rosa R, Iacobello C, Larocca L, Cappello E, et al. Treatment induced seroconversion to HBsAb following HBV reactivation in the immunosuppressed haematology and oncology patient: a clinical survey of 5 cases in Catania, Italy. J Clin Virol 2011; 52:284-287.
9. Idilman R. Lamivudine prophylaxis in HBV carriers with haemato-oncological malignancies who receive chemotherapy. J Antimicrob Chemother 2005; 55:828-831.
10. Gopal K, Min AD. Chemoprevention of patients with hepatitis B receiving chemotherapy or bone marrow transplantation. Curr Hepatitis Rep 2010; 9:178-186.
11. Marinone C, Mestriner M. HBV disease: HBsAg carrier and occult B infection reactivation in haematological setting. Dig Liver Dis 2011; 43: S49-S56.
12. Liang R. How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation. Blood 2009; 13:3147-3153.
13. Okita R, Takahashi M, Narahara H, Sanada Y, Okada M, Kawakami Y, et al. Use of entecavir to prevent hepatitis B virus reactivation during cytotoxic chemotherapy for solid malignancy. Case report. Clin J Gastroenterol 2009; 2:214-217.
14. Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000; 119:172-180.
15. Leung NW, Tam JS, Lau GT, Leung TW, Lau WY, Li AK. Hepatitis B virus DNA in peripheral blood leucocytes - a comparison between hepatocellular carcinoma and other hepatitis B virus-related chronic liver diseases. Cancer 1994; 73:1143-1148.
16. You J, Sriplung H, Geater A, Chongsuvivatwong V, Zhuang L, Li YL, et al. Impact of viral replication inhibition by entecavir on peripheral T lymphocyte subpopulations in chronic hepatitis B patients. BMC Infect Dis 2008; 8:123.
17. Yeo W, Chan PK, Zhong S, Ho WM, Steinberg JL, Tam JS, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000; 62:299-307.
18. Khokhar OS, Farhadi A, McGrail L, Lewis JH. Oncologists and hepatitis B: a survey to determine current level of awareness and practice of antiviral prophylaxis to prevent reactivation. Chemotherapy 2009; 55:69-75.
19. Tozun N, Ozdogan OC, Cakaloglu Y, Idilman R, Karasu Z, Akarca US, et al. A nationwide prevalence study and risk factors for hepatitis A, B, C and D infections in Turkey. Hepatology 2010; 52:697A.
20. Papamichalis P, Alexiou A, Boulbou M, Dalekos GN, Rigopoulou EI. Reactivation of resolved hepatitis B virus infection after immunosuppression: is it time to adopt pre-emptive therapy? Clin Res Hepatol Gastroenterol 2011; 36:84-93.
21. Tran TT, Rakoski MO, Martin P, Poordad F. Screening for hepatitis B in chemotherapy patients: survey of current oncology practices. Aliment Pharmacol Ther 2010; 31:240-246.
22. Idilman R, Arat M. Evaluation and management of hepatitis B virus infection in hematopoietic stem cell transplantation: before and after transplantation. Expert Rev Anti Infect Ther 2011; 9:641-652.
23. Colson P, Borentain P, Coso D, Chabannon C, Tamalet C, Gérolami R. Entecavir as a first-line treatment for HBV reactivation following polychemotherapy for lymphoma. Br J Haematol 2008; 143:148-150.
24. Uchiyama M, Tamai Y, Ikeda T. Entecavir as prophylaxis against hepatitis B virus reactivation following chemotherapy for lymphoma. Int J Infect Dis 2010; 14:e265-e266.
25. Rossi G, Pelizzari A, Motta M, Puoti M. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy. Br J Haematol 2001; 115:58-62.
26. Lim LL, Wai CT, Lee YM, Kong HL, Lim R, Koay E, Lim SG. Prophylactic lamivudine prevents hepatitis B reactivation in chemotherapy patients. Aliment Pharmacol Ther 2002; 16:1939-1944.
27. Hui CK, Cheung WW, Au WY, Lie AK, Zhang HY, Yueng YH, et al. Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy. Gut 2005; 54:1597-1603.
28. Lau GK, Leung YH, Fong DY, Au WY, Kwong YL, Lie A, et al. High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood 2002; 99:2324-2330.
29. Dai MS, Chao TY, Kao WY, Shyu RY, Liu TM. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP. Ann Hematol 2004; 83:769-774.
30. Iannitto E, Minardi V, Calvaruso G, Mulè A, Ammatuna E, Di Trapani R, et al. Hepatitis B virus reactivation and alemtuzumab therapy. Eur J Haematol 2005; 74:254-258.
31. Westhoff TH, Jochimsen F, Schmittel A, Stoffler-Meilicke M, Schafer JH, Zidek W, et al. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood 2003; 102:1930.
32. Idilman R, Arat M, Soydan E, Törüner M, Soykan I, Akbulut H, et al. Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies. J Viral Hepat 2004; 11:141-147.
33. Takahashi T, Koike T, Hashimoto S, Miura T, Nakamura J, Yamada S, et al. A case of lamivudine-sensitive de novo acute hepatitis B induced by rituximab with the CHOP regimen for diffuse large B cell lymphoma. Hepatol Int 2009; 3:316-322.
34. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45:507-539.
35. Yeo W, Ho WM, Hui P, Chan PK, Lam KC, Lee JJ, Johnson PJ. Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients. Breast Cancer Res Treat 2004; 88:209-215.
36. Yeo W, Chan PK, Hui P, Ho WM, Lam KC, Kwan WH, et al. Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J Med Virol 2003; 70:553-561.